术后血清CEA联合CA19-9、YKL-40、CRP和IL-6预测结直肠癌复发和生存的临床价值-现代医学

术后血清CEA联合CA19-9、YKL-40、CRP和IL-6预测结直肠癌复发和生存的临床价值

单位：西安市中心医院消化科, 陕西西安 710003

分类号：R735.34

出版年·卷·期（页码）：2022·50·第九期（1143-1150）

摘要：

目的：探讨术后血清肿瘤标志物癌胚抗原（CEA）联合糖类抗原19-9（CA19-9）、人软骨糖蛋白（YKL-40）、C反应蛋白（CRP）和白细胞介素6（IL-6）对结直肠癌（CRC）根治性切除患者复发和生存的预后价值。方法：选取2010年1月至2017年2月在我院接受根治性手术治疗的441例CRC患者作为研究对象。术后辅助化疗前采集清晨空腹静脉血，检测血清CEA、CA19-9、YKL-40、CRP、IL-6水平。随访至2021年11月或患者死亡时。采用Cox回归比例风险模型和Kaplan-Meier生存曲线分析影响术后复发和生存预后的危险因素。采用受试者工作特征（ROC）曲线分析血清学指标对于CRC的诊断和预后判断效能。结果：术后血清CEA水平预测复发的敏感度为21.3%，特异度为90.3%，阳性预测值（PPV）为80.3%。而术后血清CEA>5 μg·L^-1分别联合CA19-9、YKL-40、CRP、IL-6预测患者复发风险的敏感度和PPV均升高（P<0.05）。对于血清CEA≤5 μg·L^-1者，血清YKL-40>77.9 ng·ml^-1的患者10年总生存期（OS）和无病生存期（DFS）均短于YKL-40≤77.9 ng·ml^-1的患者（P<0.05）；另外血清CRP>2.99 mg·L^-1的患者10年OS短于CRP≤2.99 mg·L^-1的患者（P<0.05）；血清IL-6>5.4 pg·ml^-1的患者10年DFS短于IL-6≤5.4 pg·ml^-1的患者（P<0.05）。经Cox回归比例风险模型分析，CEA、CA19-9、YKL-40、IL-6升高是影响患者OS的独立危险因素，CEA、YKL-40、IL-6升高是影响患者DFS的独立危险因素（P<0.05）。结论：根治性切除术后血清CEA联合CA19-9、YKL-40、CRP、IL-6可作为结直肠癌复发和生存的预后指标。

Objective: To investigate the prognostic value of postoperative serum carcinoembryonic antigen(CEA) combined with carbohydrate antigen 19-9(CA19-9), human chondroglycoprotein(YKL-40), C-reactive protein(CRP) and interleukin 6(IL-6) in patients with colorectal cancer(CRC) after radical resection. Methods: A total of 441 CRC patients who received radical surgical treatment in our hospital from January 2010 to February 2017 were selected as the objects of this study. The levels of serum CEA, CA19-9, YKL-40, CRP and IL-6 were measured before adjuvant chemotherapy. The patients were followed up until November 2021 or at the time of death. Cox regression proportional risk model and Kaplan-Meier survival curve were used to analyze the risk factors for postoperative recurrence and survival. Receiver operating characteristic(ROC) curve was used to analyze the diagnostic or prognostic efficacy of serological indicators for CRC. Results: The sensitivity, pecificity and positive predictive value(PPV) of postoperative serum CEA in predicting the recurrence were 21.3%, 90.3% and 80.3% respectively. The sensitivity and PPV of postoperative serum CEA>5 μg·L^-1 combined with CA19-9, YKL-40, CRP and IL-6 in predicting the recurrence were increased(P<0.05). For patients with postoperative serum CEA ≤ 5 μg·L^-1, 10-year overall survival(OS) and disease-free survival(DFS) of patients with serum YKL-40>77.9 ng·ml^-1 were shorter than those with serum YKL-40 ≤ 77.9 ng·ml^-1(P<0.05). In addition, the 10-year OS of patients with serum CRP>2.99 mg·L^-1 was shorter than that of patients with CRP ≤ 2.99 mg·L^-1(P<0.05). The 10-year DFS of patients with serum IL-6>5.4 pg·ml^-1 was shorter than that of patients with IL-6 ≤ 5.4 pg·ml^-1(P<0.05). Cox regression proportional risk model analysis showed that the increase of CEA, CA19-9, YKL-40 and IL-6 were independent risk factors affecting OS, while the increase of CEA, YKL-40 and IL-6 were independent risk factors affecting DFS(P<0.05). Conclusion: Serum CEA combined with CA19-9, YKL-40, CRP and IL-6 after radical resection can be used as prognostic indicators for colorectal cancer recurrence and survival.

参考文献：

[1] 方敏, 吕嘉晨.结直肠癌筛查的现状、进展及问题思考[J].医学与哲学, 2021, 42(11):17-22.
[2] 林宇挺, 熊海林.Ⅱ~Ⅲ期结直肠癌中Vasohibin-1的表达及复发转移预后分析[J].中国肿瘤外科杂志, 2021, 13(5):484-488.
[3] GAO Y, WANG J, ZHOU Y, et al. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer[J].Sci Rep, 2018, 8(1):2732-2740.
[4] KONISHI T, SHIMADA Y, HSU M, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome[J].JAMA Oncol, 2018, 4(3):309-315.
[5] SJIN J K, KIM H C, LEE W Y, et al. High preoperative serum CA 19-9 levels can predict poor oncologic outcomes in colorectal cancer patients on propensity score analysis[J].Ann Surg Treat Res, 2019, 96(3):107-115.
[6] 王逸君, 张碧云, 陈乐君, 等.炎症及营养指标与直肠癌新辅助放化疗病理反应及患者预后的相关性研究[J].东南大学学报(医学版), 2021, 40(5):578-585.
[7] HERMUNEN K, SOVERI L M, BOISEN M K, et al. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer[J].Acta Oncol, 2020, 59(12):1416-1423.
[8] EBRAHIM A, MUSTAFA A I, EL-SHIMI O S, et al. Serum YKL40:a novel potential link between inflammation and dyslipidemia in acne vulgaris[J].J Cosmet Dermatol, 2020, 19(5):1219-1223.
[9] MILONE M, DESIDERIO A, VELOTTI N, et al. Surgical stress and metabolic response after totally laparoscopic right colectomy[J].Sci Rep, 2021, 11(1):9652-9662.
[10] NASR R, SALIM HAMMOUD M, NASSAR F, et al. Inflammatory markers and microRNAs:the backstage actors influencing prognosis in colorectal cancer patients[J].Int J Mol Sci, 2018, 19(7):1867-1880.
[11] 杨晓飞, 于丽娜, 刘京. 肿瘤标志物、血清炎症因子和协同共刺激分子B7-H6的表达在宫颈癌中的临床价值研究[J].现代医学, 2021, 49(11):1267-1272.
[12] 郭庆伟, 徐志诚, 崔永欣. 结直肠癌术前不同CEA水平对患者预后及复发转移的影响[J].实用癌症杂志, 2019, 34(4):561-563.
[13] PESTA M, KUCERA R, TOPOLCAN O, et al. Plasma microRNA levels combined with CEA and CA19-9 in the follow-up of colorectal cancer patients[J].Cancers(Basel), 2019, 11(6):864-878.
[14] LEE T, TENG T Z J, SHELAT V G. Carbohydrate antigen 19-9-tumor marker:past, present, and future[J].World J Gastrointest Surg, 2020, 12(12):468-490.
[15] ZHOU W, YANG F, PENG J, et al. High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy[J].J Cancer, 2019, 10(16):3810-3818.
[16] JIN L J, CHEN W B, ZHANG X Y, et al. Analysis of factors potentially predicting prognosis of colorectal cancer[J].World J Gastrointest Oncol, 2019, 11(12):1206-1217.
[17] 杨少辉, 刘开泰, 赵逸斌, 等.血清YKL-40在结直肠癌诊断及筛查中的应用价值[J].现代实用医学, 2022, 34(4):465-467.
[18] LEHTOMAKI K, MUSTONEN H, KELLOKUMPU-LEHTINEN P L, et al. Lead time and prognostic role of serum CEA, CA19-9, IL-6, CRP, and YKL-40 after adjuvant chemotherapy in colorectal cancer[J].Cancers(Basel), 2021, 13(15):3892-3907.
[19] VAINER N, DEHLENDORFF C, JOHANSEN J S. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer[J].Oncotarget, 2018, 9(51):29820-29841.
[20] 熊咏, 沈容荣, 刘东洋.血清中白细胞介素-6及癌胚抗原对结直肠癌术后复发的预测作用[J].中国当代医药, 2022, 29(2):11-14.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录